

## Guideline/Protocol-Related Records of Decisions under the Laboratory Services Act

In accordance with Section 23(3) of the Laboratory Services Act, the following <a href="#">BC Guidelines and Protocols</a> are adopted.	
LSA2024-038	<b>Antinuclear Antibody (ANA) Testing Guideline</b> Effective October 23, 2024, the Ministry of Health adopted the Antinuclear Antibody (ANA) Testing Guideline under the LSA. This guideline supersedes the previous version of the guideline, Antinuclear Antibody (ANA) Testing Protocol (2013), which was adopted under Record of Decision # LSA2017-038.
LSA2024-012	<b>Venous Thromboembolism – Diagnosis and Management Guideline</b> Effective February 21, 2024, the Ministry of Health adopted the Venous Thromboembolism (VTE) – Diagnosis and Management Guideline under the LSA. This guideline is new for 2024.
LSA2024-001	<b>High-Risk Drinking and Alcohol Use Disorder Guideline</b> Effective February 21, 2024, the Ministry of Health adopted the High-Risk Drinking and Alcohol Use Disorder (AUD) Guideline under the LSA. This guideline supersedes the previous version of the guideline, Problem Drinking Guideline (2013), which was adopted under Record of Decision # LSA2017-038.
LSA2024-002	<b>Chronic Obstructive Pulmonary Disease (COPD): Diagnosis and Management in Primary Care Guideline</b> Effective January 17, 2024, the Ministry of Health adopted the Chronic Obstructive Pulmonary Disease (COPD): Diagnosis and Management in Primary Care Guideline under the LSA. This guideline supersedes the previous version of the guideline, Chronic Obstructive Pulmonary Disease (COPD): Diagnosis and Management Guideline (2017), which was adopted under Record of Decision # LSA2017-038.
LSA2023-010	<b>Heart Failure – Diagnosis and Management Guideline</b> Effective July 26, 2023, the Ministry of Health adopted the Heart Failure – Diagnosis and Management Guideline under the LSA. This guideline supersedes the previous version of the guideline, Chronic Heart Failure – Diagnosis and Management, which was adopted under Record of Decision # LSA2017-038.
LSA2023-009	<b>Atrial Fibrillation – Diagnosis and Management Guideline</b> Effective July 26, 2023, the Ministry of Health adopted the Atrial Fibrillation – Diagnosis and Management Guideline under the LSA. This guideline supersedes the previous version of the guideline, which was adopted under Record of Decision # LSA2017-038.
LSA2023-001	<b>Cobalamin (Vitamin B12) and Folate Deficiency Guideline</b> Effective January 18, 2023, the Ministry of Health adopted the Cobalamin (Vitamin B12) and Folate Deficiency Guideline under the LSA. This guideline supersedes and combines the previous guidelines, Cobalamin (Vitamin B12) Deficiency – Investigation and Management and Folate Deficiency – Investigation and Management, which were adopted under Record of Decision # LSA2017-038.
LSA2022-044	<b>Direct Acting Oral Anticoagulants (DOACs) Guideline</b> Effective January 18, 2023, the Ministry of Health adopted the amended Direct Acting Oral Anticoagulants Guideline under the LSA. This guideline supersedes the previous version of the guideline, Use of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Non-Valvular Atrial Fibrillation Guideline, which was adopted under Record of Decision # LSA2017-038.

## Guideline/Protocol-Related Records of Decisions under the Laboratory Services Act

LSA2022-043	<b>Oral Anticoagulants: Elective Interruption &amp; Emergency Reversal Guideline</b> Effective January 18, 2023, the Ministry of Health adopted the amended Oral Anticoagulants: Elective Interruption & Emergency Reversal Guideline under the LSA. This guideline supersedes the previous guideline, Warfarin Therapy – Management During Invasive Procedures and Surgery Guideline, which was adopted under Record of Decision # LSA2017-038.
LSA2022-042	<b>Warfarin Guideline</b> Effective January 18, 2023, the Ministry of Health adopted the amended Warfarin Guideline under the LSA. This guideline supersedes the previous version of the guideline, which was adopted under Record of Decision # LSA2017-038.
LSA2022-039	<b>Hormone Testing – Indications and Appropriate Use Guideline</b> Effective October 27, 2022, the Ministry of Health adopted the amended Hormone Testing – Indications and Appropriate Use Guideline under the LSA. This guideline supersedes the previous version of the guideline, Special Endocrine Testing, which was adopted under Record of Decision # LSA2017-038.
LSA2022-036	<b>Testosterone Testing Protocol</b> Effective October 27, 2022, the Ministry of Health adopted the amended Testosterone Testing Protocol under the LSA. This guideline supersedes the previous version of the guideline, which was adopted under Record of Decision # LSA2018-019.
LSA2022-019	<b>Infectious Diarrhea – Guideline for Investigation</b> Effective October 27, 2022, the Ministry of Health adopted the amended Infectious Diarrhea – Guideline for Investigation under the LSA. This guideline supersedes the previous version of the guideline, Infectious Diarrhea – Guideline for Ordering Stool Specimens, which was adopted under Record of Decision # LSA2017-038.
LSA2022-007	<b>Colorectal Cancer Guideline – Part 1 Screening for the Purposes of Colorectal Cancer Prevention and Detection in Asymptomatic Adults and Part 2 Follow-up of Colorectal Cancer and Precancerous Lesions (Polyps)</b> Effective April 13, 2022, the Ministry of Health adopted the amended Colorectal Cancer Guideline – Part 1: Screening for the Purposes of Colorectal Cancer Prevention and Detection in Asymptomatic Adults and Part 2: Follow-up of Colorectal Cancer and Precancerous Lesions (Polyps) under the LSA. This guideline supersedes the previous version of the guideline, which was adopted under Record of Decision # LSA2017-038.
LSA2021-023	<b>Cardiovascular Disease – Primary Prevention Guideline</b> Effective December 8, 2021, the Ministry of Health adopted the amended Cardiovascular Disease – Primary Prevention Guideline under the LSA. This guideline supersedes the previous version of the guideline, which was adopted under Record of Decision # LSA2021-010.
LSA2021-024	<b>Diabetes Care Guideline</b> Effective October 27, 2021, the Ministry of Health adopted the amended Diabetes Care Guideline under the LSA. This guideline supersedes the previous version of the guideline, which was adopted under Record of Decision # LSA2017-038.

## Guideline/Protocol-Related Records of Decisions under the Laboratory Services Act

LSA2021-011	<b>High-Ferritin and Iron Overload Guideline</b> Effective June 30, 2021, the Ministry of Health adopted the amended High-Ferritin and Iron Overload Guideline under the LSA. This guideline supersedes the previous version of the guideline, HFE-Associated Hereditary Hemochromatosis Investigations and Management, which was adopted under Record of Decision # LSA2017-038.
LSA2021-005	<b>Viral Hepatitis Testing Guideline</b> Effective May 26, 2020, the Ministry of Health adopted the amended Viral Hepatitis Testing Guideline under the LSA. This guideline supersedes the previous version of the guideline, which was adopted under Record of Decision # LSA2017-038.
LSA2021-010	<b>Cardiovascular Disease – Primary Prevention Guideline</b> Effective October 28, 2020, the Ministry of Health adopted the amended Cardiovascular Disease – Primary Prevention Guideline under the LSA. This guideline supersedes the previous version of the guideline, Cardiovascular Disease – Primary Prevention Guideline, which was adopted under Record of Decision # LSA2017-038.
LSA2020-020	<b>Workup of Microscopic Hematuria Guideline</b> Effective July 29, 2020, the Ministry of Health adopted the amended Workup of Microscopic Hematuria Guideline under the LSA. This guideline supersedes the previous version of the guideline, Microscopic Hematuria (Persistent), which was adopted under Record of Decision #LSA2017-038.
LSA2020-019	<b>Urinary Tract Infections in the Primary Care Setting Investigation Protocol</b> Effective July 29, 2020, the Ministry of Health adopted the amended Urinary Tract Infections in the Primary Care Setting Investigation Protocol under the LSA. This protocol supersedes the previous version of the guideline, Macroscopic and Microscopic Urinalysis and the Investigation of Urinary Tract Infections, which was adopted under Record of Decision #LSA2017-038.
LSA2020-015	<b>Prostate Cancer Guideline – Part 1 Diagnosis and Referral in Primary Care and Part 2 Follow-up in Primary Care</b> Effective April 15, 2020, the Ministry of Health adopted the new Prostate Cancer Guideline – Part 1: Diagnosis and Referral in Primary Care and Part 2: Follow-up in Primary Care under the LSA.
LSA2020-014	<b>Hypertension – Diagnosis and Management Guideline</b> Effective April 15, 2020, the Ministry of Health adopted the amended Hypertension – Diagnosis and Management Guideline under the LSA. This guideline supersedes the previous version of the guideline which was adopted under Record of Decision # LSA2017-038.
LSA2020-001	<b>Vitamin D Testing Guideline</b> Effective October 30, 2019, the Ministry of Health adopted the amended Vitamin D Testing Guideline under the LSA. This guideline supersedes the previous guideline, Vitamin D Testing Protocol, which was adopted under Record of Decision # LSA2017-038.
LSA2019-016	<b>Iron Deficiency – Diagnosis and Management Guideline</b> Effective August 1, 2019, the Ministry of Health adopted the Iron Deficiency – Diagnosis and Management Guideline under the LSA.
LSA2019-004	<b>C-Reactive Protein and Erythrocyte Sedimentation Rate Testing</b> Effective February 28, 2019, the Ministry of Health adopted the C-Reactive Protein and Erythrocyte Sedimentation Rate Protocol under the LSA.

## Guideline/Protocol-Related Records of Decisions under the Laboratory Services Act

LSA2018-023	<p><b>Thyroid Function Testing in the Diagnosis and Monitoring of Thyroid Function Disorder</b> Effective November 22, 2018, the Ministry of Health adopted the Thyroid Function Testing in the Diagnosis and Monitoring of Thyroid Function Disorder Protocol under the LSA.</p>
LSA2018-019	<p><b>Revised GPAC Testosterone Testing Protocol</b> Effective September 27, 2018, the Ministry of Health adopted the Testosterone Testing Protocol under the under the LSA.</p>
LSA2017-038	<p><b>Rescind Record of Decision LSA2015-007 and Adopt Existing BC Clinical Guidelines and Protocols</b> Effective January 2, 2018, the Ministry of Health adopted the existing BC Clinical Guidelines and Protocols under the under the LSA.</p>
LSA2017-038 (Cont'd)	<p><b>2016</b> Cognitive Impairment – Recognition, Diagnosis and Management in Primary Care Colorectal Screening for Cancer Prevention in Asymptomatic Patients Special Endocrine Testing Female Genital Tract Cancers: Human Papillomavirus Related Cancers (Cervical, Vaginal &amp; Vulvar) Hypertension – Diagnosis and Management</p>
	<p><b>2015</b> Asthma (Adult) – Recognition, Diagnosis and Management Asthma (Children) – Diagnosis and Management Atrial Fibrillation – Diagnosis and Management Chronic Heart Failure – Diagnosis and Management Diabetes Care Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Non-Valvular Stroke and Transient Ischemic Attack – Acute and Long-Term Management Warfarin Therapy Management Warfarin Therapy – Management During Invasive Procedures and Surgery</p>
	<p><b>2014</b> Ankle Injury – X-ray for Acute Injury Cardiovascular Disease – Primary Prevention Chronic Kidney Disease – Identification, Evaluation and Management of Adult Female Genital Tract Cancers: Endometrial Cancer Female Genital Tract Cancers: Ovarian, Fallopian Tube and Primary Peritoneal</p>

## Guideline/Protocol-Related Records of Decisions under the Laboratory Services Act

LSA2017-038 (Cont'd)	<b>2013</b> Ambulatory ECG Monitoring Antinuclear Antibody (ANA) Testing for Connective Tissue Disease Breast Disease and Cancer – Diagnosis Breast Cancer - Management and Follow-up Cobalamin Deficiency – Investigation and Management Depression (MDD) in Adults – Diagnosis and Management Follow-up of Colorectal Polyps or Cancer Hemochromatosis – Investigations and Management Problem Drinking Part 1: Screening and Assessment Problem Drinking Part 2: Brief Intervention Problem Drinking Part 3: Office-based Management Vitamin D
	<b>2012</b> Folate Deficiency – Investigation and Management Viral Hepatitis Testing Osteoporosis – Diagnosis and Treatment Rheumatoid Arthritis – Diagnosis and Management
	<b>2011</b> Liver Chemistry Abnormalities in Adults Testosterone Testing Overweight and Obese Adults – Diagnosis and Management
	<b>2010</b> Anxiety and Depression in Children and Youth Febrile Seizures Iron Deficiency – Investigation and Management Oral Rehydration Therapy Otitis Media (Acute or with Effusion) Thyroid Function Tests in the Diagnosis and Monitoring of Adults
	<b>2009</b> Dyspepsia with or without H pylori infection Gastroesophageal Reflux Disease (GERD) Hematuria – Microscopic (persistent) Infectious Diarrhea – Guideline for Ordering Stool Samples Osteoarthritis in Peripheral Joints – Primary Care Management Urinary Tract Infections – Macroscopic and Microscopic Urinalysis
	<b>2007</b> Cataract – Treatment of Adults Erythrocyte Sedimentation Rate (ESR) Sleep Complaints in Adults – Primary Care Management

